Floatz logo

CNTO 0007

Ischemia

Janssen Research & Development, LLCPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Ischemia cohort.

Asset / SponsorPhaseRating
Acetylsalicylic Acid
Xijing Hospital
Phase 4BBB
Pregabalin
Karolinska Institutet
Phase 4BB
UROKINASE-TYPE PLASMINOGEN ACTIVATOR
medac GmbH
Phase 3BB
Vorapaxar
Merck Sharp & Dohme LLC
Phase 3B
Tocilizumab
Zhujiang Hospital
Phase 3B

View all 10 →

Same molecule, other indications

CNTO 0007 is also rated in:

cerebral infarctionDormant
CC
Indicative ·
47 / 100
View asset →
stroke disorderDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →